Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Healthcare

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

TSX:MDP - Post by User

Medexus Pharmaceuticals Inc

Bullboard Posts

Post by Billzareon Jul 05, 2018 9:52am

212 Views

Post# 28271700

Email from CEO - Q4

So I contacted the company this morning and got an answer almost immediately.
I'm french speaking and the CEO answered me in French so I don't need any translation :P

''Bonjour,

Nous ne divulguons pas les dates prvues des missions des tats financiers et donc, cette date du 4 juillet tait certainement de la spculation par quelqu'un non li Pediapharm. La date limite est le 31 juillet mais nous visons toujours d'tre bien l'avance. Malheureusement, je ne peux en dire plus.
Bonne journe,

Roland Boivin
CFO, Pediapharm Inc.''

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?